# Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Relative to Yaz®

> **NCT06233071** · PHASE1 · UNKNOWN · sponsor: **Bio-innova Co., Ltd** · enrollment: 32 (estimated)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Drospirenone+ Ethinyl Estradiol Tablets-Test product
- **DRUG:** Drospirenone+ Ethinyl Estradiol Tablets-Reference product

## Key facts

- **NCT ID:** NCT06233071
- **Lead sponsor:** Bio-innova Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-02-13
- **Primary completion:** 2024-04-04
- **Final completion:** 2024-05-02
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06233071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06233071, "Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Relative to Yaz®". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06233071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*